Impact of pretransplant antibodies on outcomes after heart transplantation

Shinichi Nunoda

Purpose of review
Since the discovery of human leukocyte antigen (HLA) in the 1950s, there has been great interest in the role of antibodies in posttransplant rejection. The development of the lymphocyte toxicity test by Terasaki et al. in the 1960s was the first step toward understanding the role of antibodies in posttransplant rejection.

Recent findings
Subsequently, various organs have been transplanted and improving posttransplant outcomes have become a focus of research. In particular, methods to measure antibodies that affect posttransplant outcomes, including anti-HLA antibodies, and methods to desensitize patients from specific antibodies have been explored. One recent method for measuring antibodies is called the solid-phase assay, which uses purified HLA fixed to microbeads. This assay does not use donor lymphocytes and allows clinicians to test the reactivity of patient serum against a panel of antibodies. It has also enabled the identification of specific anti-HLA antibodies using a single HLA.

Summary
In addition to advances in methods to measure and analyze anti-HLA antibodies, the clinical impact of non-HLA antibodies has also received much attention recently.

Keywords
crossmatching, donor-specific antibodies, nonhuman leukocyte antigen antibodies, sensitization, solid-phase assay

INTRODUCTION
To properly discuss antihuman leukocyte antigen (HLA) antibodies in the context of pretransplant antibodies, a brief historical account is necessary.

Dausset discovered HLA antigens in the 1950s as a type of protein on leukocytes. HLA antibodies were subsequently found to be a cause of rejection in patients with kidney transplants [1].

In the 1960s, Terasaki and McClelland developed the lymphocyte cytotoxicity test (LCT) to detect anti-HLA antibodies [2]. The LCT is a useful method of detection that is still currently used [2]. Subsequently, various other methods of detection that do not rely on donor lymphocytes have been developed, including flow cytometry crossmatching (FCM) in the 1980s, which uses flow cytometry to crossmatch lymphocytes with high sensitivity; enzyme-linked immunosorbent assay in the 1990s, which uses purified HLA antigens fixed to microplates; and solid-phase assay, which uses purified HLA antigens fixed to microbeads [3].

MECHANISM OF ANTIBODY PRODUCTION AND ALLOGRAFT INJURY BY ANTIBODIES IN SENSITIZED PATIENTS
HLA molecules are categorized as class I (A, B, C) or class II (DR, DQ, DP). They are located in different regions of chromosome 6. HLA expression on the cell surface enables recognition of self from nonself.

Department of Therapeutic Strategy for Severe Heart Failure, Graduate School of Medicine, Tokyo Women’s Medical University, Tokyo, Japan
Correspondence to Shinichi Nunoda, MD, PhD, Department of Therapeutic Strategy for Severe Heart Failure, Graduate School of Medicine, Tokyo Women’s Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan. Tel: +81 3 3353 8111; e-mail: ie9s-nnd@asahi-net.or.jp

Curr Opin Organ Transplant 2019, 24:220–226
DOI:10.1097/MOT.0000000000000629
This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Class I HLA molecules are constitutively expressed on all nucleated cells, whereas class II HLA expression is restricted to B cells, activated T cells, and antigen-presenting cells (APCs). Class II expression may be induced on certain cell types, such as endothelial cells, under the influence of cytokine activation, which occurs with ischemia–reperfusion injury. HLA class I or II expression on allograft vascular endothelial cells can account for rejection occurring in the presence of class I or class II donor-specific antibodies (DSAs).

Antibody production begins with the exposure of naive B cells to an antigen in the presence of APCs or T-helper cells in secondary lymphoid tissues. These stimulated B cells become either plasmablasts secreting low-affinity antibodies or activated B cells that interact with follicular dendritic and T-helper follicular cells to form germinal centers [4]. B cells undergo proliferation, hypermutation, and affinity maturation to become memory B cells or differentiated plasma cells that secrete high-affinity antibodies. Memory B cells circulate through secondary lymphoid organs and in the peripheral circulation. Memory B cells rapidly proliferate upon reexposure to an antigen and differentiate into plasma cells that produce high-affinity antibodies.

Allograft injury by antibodies occurs predominantly through complement activation. Binding of antibodies to HLA antigen results in activation of C1q and the complement cascade. Complement-independent injury by DSA also occurs through Fc receptor recruitment of inflammatory cells and the release of inflammatory mediators. Antimajor histocompatibility complex (MHC) antibodies may either result in direct injury to the capillary endothelium or indirect injury via complement fixation or recruitment of inflammatory cells with Fc receptors [5]. As a result, cellular inflammation, thrombosis, hemorrhage, and lysis cause cardiac allograft dysfunction.

**RISK FACTORS FOR SENSITIZATION**

Risk factors for sensitization include blood transfusion, prior transplantation, pregnancy, use of homografts in prior cardiac surgeries, and ventricular assist device (VAD) use prior to transplantation [6–10,11].

Among transfusion recipients, 20% demonstrate sensitization, compared with 3% who do not [12]. Multiparous women are at risk of sensitization to paternal antigens [13]. VADs increase the risk of sensitization because of the higher likelihood of needing blood transfusions, although biomaterials and textured surfaces have also been implicated in increasing immunologic risk through allo sensitization. Half of all patients currently undergoing heart transplantation are now bridged with VADs [14]. Sensitization occurs most frequently before transplantation when the underlying condition is myocarditis or repeated infections during VAD use. Sensitization after VAD implantation increases the risk of posttransplant rejection, including hyperacute rejection and primary graft dysfunction [15,16].

**CLINICAL IMPLICATIONS OF SENSITIZATION**

In heart transplant patients, patients with panel-reactive antibody (PRA) more than 10% have been shown to be at risk for earlier and more severe rejection as well as worse survival [17–21]. In a study involving 8160 heart transplant recipients, Nwakanma et al. [22] demonstrated that sensitization defined as PRA more than 25% is associated with a significant decrease in survival up to 5 years after heart transplantation ($P<0.007$) and a higher incidence of rejection ($P=0.017$). At 5 years, survival in patients with PRA more than 25% was 65% compared with 74% in patients with PRA less than equal to 25%. More recently, Potena et al. [23] demonstrated that pretransplantation HLA antibodies are associated with worse survival (65 ± 9% versus 82 ± 3%; $P=0.02$). Based on these studies, sensitization prior to cardiac transplantation is a well-established risk factor for survival.

The most severe conditions associated with DSAs in heart transplantation are hyperacute rejection and acute posttransplant heart failure, which can occur within minutes to hours after transplantation. Severe posttransplant cardiac dysfunction...
occurs when a high titer of DSAs reacts with the vascular endothelium of the transplanted heart in the recipient even during transplantation, which initiates a complement-binding reaction in blood vessels leading to cell death, activation of inflammatory cells, and platelet aggregation within minutes to hours after reperfusion. Ultimately, this causes diffuse ischemia and necrosis in the transplanted heart, which is life-threatening [24–27].

Although HLA class II antigens are not normally expressed in the transplanted heart, expression can be induced through inflammation and dysfunction introduced during organ extraction and storage [28]. Furthermore, non-HLA antibodies can also cause acute antibody-mediated rejection (AMR) [29].

Given that positive DSA status results in poor postheart transplant prognosis, many countries have instituted screening tests for HLA antibodies in patients waiting for transplantation. As a result, the incidence of hyperacute rejection has decreased dramatically [21,30]. However, AMR is now known to contribute to the progression of cardiac allograft vasculopathy (CAV) [31]. It has recently become a focus of attention more than 10 years after it was first described [32].

Regarding the timing of sensitization, Ho et al. [33] reported that the 15-year survival rate was 70% in patients negative for anti-HLA antibodies, 71% in patients positive for anti-HLA antibodies only before transplantation, and 56% in patients positive for anti-HLA antibodies before and after transplantation. Patients with de novo antibodies that appear more than one year after transplantation had the worst prognosis, with a 15-year survival rate of 47%. Recent data demonstrated that preformed HLA antibodies are associated with an increased occurrence of a composite endpoint of death, graft loss or retransplantation, biopsy-proven acute rejection, and CAV ($P < 0.04$). HLA class I antibodies were more prevalent among those who reached this endpoint than those who did not ($P < 0.01$), but there were no differences in anticlass II antibodies between patients who met the endpoint and those who did not [34].

CAV has been reported to progress rapidly in patients with HLA class II DSA [35]. Tran et al. [36] found that 88% of prolonged DSA expression was HLA class II antibodies in pediatric DSA patients. The presence of DQ antibodies resulted in the worst prognosis [37].

Recent strategies to combat DSAs include desensitization therapy followed by a short waiting time to transplantation [38,39]. Other measures such as minimizing transfusions or reducing exposure to HLA antigens through radiation therapy or leukocyte removal are also important [26,40].

**METHODS TO ASSESS HUMAN LEUKOCYTE ANTIGEN ANTIBODIES AND CROSSMATCHING**

In 1969, crossmatching based on complement-dependent cytotoxicity (CDC) was used for detecting DSAs associated with acute rejections. CDC detects complement-dependent antibodies in patient serum using donor lymphocytes as the standard. Thus, it is sometimes called LCT. Since it was first described, LCT has become widely used. Its sensitivity has improved through the addition of antihuman globulins (AHGs) [41]. However, an adequate correlation between LCT results and clinical symptoms has not been well described, and other highly sensitive methods of detecting antibodies such as FCM and solid-phase assays using purified HLA antigens have been developed Table 1.

Crossmatching can be subdivided into two major types: direct crossmatching, which involves direct reactions between patient serum and donor lymphocytes, and virtual crossmatching, which uses immobilized HLA antigens instead of donor lymphocytes. The most effective crossmatching method is to first use highly sensitive virtual crossmatching followed by direct crossmatching as a confirmatory test.

The possibility of false-positive reactions exists in patients waiting for organ transplants, as they are sometimes treated with antibody therapies such as rituximab. Therefore, antibody detection tests should be performed before antibody-based therapy.

**Direct crossmatching**

**Complement-dependent cytotoxicity or lymphocyte cytotoxicity test method**

The method involves reacting patient serum with donor lymphocytes, adding rabbit complement, and visualizing cell damage because of the antigen–antibody reactions using a dye such as eosin. The advantages of this method include the ability to detect cell damage caused by non-HLA antibodies because the reaction conditions closely mimic in-vivo conditions. In contrast, disadvantages include difficulties in preparing donor lymphocytes and variations in results on the basis of technical expertise and experience, as part of the method involves visualization. Nonspecific reactions due to IgM antibodies may also occur, hampering detection and necessitating care when using this method. Although attempts at increasing the sensitivity of antibody detection have been made, for example, by introducing AHGs before the addition of the rabbit complement (AHG–LCT method), its sensitivity is lower compared with FCM method and solid-phase assay.
Flow cytometry crossmatching method

The method involves reacting patient serum with donor lymphocytes and adding a fluorescent-labeled antihuman immunoglobulin secondary antibody, which labels the antibodies bound to lymphocytes. FCM can then be used to detect shifts in the distribution of fluorescence signals. As FCM involves counting bound antibodies and lymphocytes, this method can be used to detect anti–non-HLA antibodies; however, it cannot be used to assess complement-binding antibodies. FCM is more sensitive at detecting physiological reactions than LCT. Consequently, this method is widely used for crossmatching in countries with more patients requiring organ transplant.

Virtual crossmatching

The method involves reacting patient serum with HLA antigens fixed onto microbeads and detecting signals from bound anti-HLA antibodies using a specialized device (solid-phase assay). The platform for detection includes a flow cytometer [42] or Luminex [43]. Depending on the type of the purified HLA antigen on the beads, panel reactive antibodies (PRAs) or the single-antigen bead (SAB) method can be used.

Panel-reactive antibodies

Traditionally, PRA was conducted used human lymphocytes; however, currently, the microbeads on the panel are coated with purified HLA antigens from human lymphocytes.

Single-antigen bead assay

The microbeads are coated with purified HLA antigens synthesized through genetic engineering. A specific anti-HLA antibody can be detected using a single HLA antigen of interest. SAB assays are now commonly deployed for determination of multiple antibody specificities and antibody quantification.

Mean fluorescence intensity

In the Luminex method, purified HLA antigens are fixed onto fluorescent polystyrene Luminex beads and reacted with anti-HLA antibodies in patient serum. The antibody–bead complex is detected with a fluorescent phycoerythrin-labeled antihuman immunoglobulin as a secondary antibody via the Luminex platform. Fluorescent-labeled detection occurs via a red laser that detects the type of Luminex bead, and therefore the HLA antigen on the bead, and a green laser that detects phycoerythrin on the secondary antibody.

Mean fluorescence intensity (MFI) is used as a readout of Luminex fluorescence values and represents the fluorescence intensity of the signal emitted by the phycoerythrin of each Luminex bead. Laboratories will typically perform validation studies to determine the relationship between antibody levels determined using SABs and flow crossmatching. For this purpose, the strength of antibody binding on SABs as represented by MFI is compared with the degree of flow crossmatching.

In general, MFI levels more than 1000 or more than 5000 are used for reporting positive results;
levels more than 8000 or more than 10,000 might correspond to cytotoxic antibodies and are clinically significant. MFI is affected by several technical and biologic factors. Antigen density on beads may vary depending on HLA molecule type and assay manufacturer or batch. Antigen density on beads may not reflect the natural expression of HLA molecules on cells in vivo. Therefore, HLA antibodies may remain undetected if they are unable to bind to the distorted HLA molecule. Conversely, clinically irrelevant antibodies that bind to denatured but not intact antigen may be detected.

**C1q ASSAY**

Conventional solid-phase assays do not discriminate between complement-fixing and non-complement-fixing antibodies and the intensity of antibodies by MFI may not be the best test of potential cytotoxicity because not all antibodies at high intensity may be detrimental to graft function. A novel C1q assay, based on the binding of HLA antibodies to C1q, which is required for the activation of the complement cascade through the classical pathway that leads to cell injury and death, has been developed [44]. The C1q assay appears to be much more sensitive than the standard CDC assay at detecting complement-fixing antibodies; however, they reported that C1q fixation is independent of MFI values [45]. In addition, Schaub et al. [46] have demonstrated that a negative C1q assay result does not always indicate the absence of strong complement-binding IgG subclasses.

**NONHUMAN LEUKOCYTE ANTIGEN ANTIBODIES**

AMR can occur with non-DSA or non-HLA antibodies. These antibodies can bind to the vascular endothelium and induce apoptosis independent of CDC. Representative examples include MHC I chain-related gene A (MICA) [47,48], angiotensin II type I receptor (AT1R) [49,50], endothelin-1 type A receptor (ETAR) [51], endothelial cell antigens [52], vimentin [53], K-α-1-tubulin [54], collagen-V [55], antiacardiac myosin antibody [56], and other non-HLA IgM antibodies. In cardiac transplantation, anti-MICA and antiendothelial antibodies have been associated with increased AMR [57] and the development of CAV [47,56]. AT1R and ETAR have been implicated in the development of acute cellular rejection, AMR, and early-onset microvasculopathy [51].

These non-HLA antibodies have been reported to cause posttransplant AMR and CAV and worsen survival [54,58–60]. However, methods to quantify non-DSA and non-HLA antibodies are in development. Currently, there are no established desensitization therapies for non-DSA and non-HLA antibodies.

**MONITORING OF SENSITIZED PATIENTS AWAITING TRANSPLANTATION**

Circulating antibodies need to be periodically monitored while awaiting heart transplantation. If PRAs increase to above 10%, further evaluations are required. For example, details such as the complement-binding ability of the detected antibodies and specificity toward anti-HLA class I and II (such as HLA A, B, Cw, DR, and DQ antigens) are required, in addition to determining DSA levels, which might increase the risk of rejection [38,61]. Patients susceptible to sensitization, such as patients with a history of PRA-positive assay results, transfusion, pregnancy, homograft transplantation, transplantation, and VAD use, should undergo anti-HLA antibody evaluation prior to transplantation [61].

Anti-HLA antibodies should be periodically monitored in patients undergoing desensitization therapy until a compatible donor can be found. Anti-HLA antibody testing should be performed every 6 months for stable nonsensitized patients. Testing should occur 2–4 weeks after transfusion in heart transplant candidates. Currently, there are no recommendations for the timing of anti-HLA antibody testing in patients with infections or using VADs. Each medical institution is responsible for determining its own testing schedules.

**CONCLUSION**

Since the development of the LCT in the 1960s by Terasaki et al., antibodies have been known to affect posttransplant outcomes. In particular, the solid-phase assay, which involves fixing purified HLA onto microbeads, enabled pretransplant reactivity of patient serum to be determined without using donor lymphocytes. The solid-phase assay has allowed specific anti-HLA antibodies to be identified. Advances in methods to measure and analyze anti-HLA antibodies, as well as the clinical impact of non-HLA antibodies, is becoming a focus of research. Future studies should focus on the impact of non-HLA antibodies on posttransplant prognosis.

**Acknowledgements**

None.

**Financial support and sponsorship**

None.
Impact of pretransplant antibodies on outcomes

23. Potena L, Bontadini A, Ianneli S, et al. Occurrence of fatal and nonfatal adverse outcomes after heart transplantation in patients with pretransplant noncytotopic HLA antibodies. J Transplant 2013; 2013:S19680.

24. Lindenfeld J, Miller GG, Shaker SF, et al. Drug therapy in the heart transplant recipient: part I: cardiac rejection and immunosuppressive drugs. Circulation 2004; 110:3734–3740.

25. Parham P. The immune system. fourth ed. New York: W. W. Norton & Company; 2014.

26. Costanzo MR, Dipchand A, Starling R, et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant 2010; 29:914–956.

27. Cai J, Terasaki PI. Humoral theory of transplantation: mechanism, prevention, and treatment. Hum Immunol 2005; 66:334–342.

28. Schrör K, Farr MA, Restano SJ, et al. Donor-specific anti-HLA antibodies with antibody-mediated rejection and long-term outcomes following heart transplantation. J Heart Lung Transplant 2017; 36:540–545.

29. The study shows that class II donor-specific antibodies provided prognostic information regarding future pathologic antibody-mediated rejection (pAMR), graft dysfunction with pAMR, and graft loss.

30. Delgado JF, Sanchez V, de la Caba da CS. Acute rejection after heart transplantation. Expert Opin Pharmacother 2006; 7:1139–1149.

31. Mangiola M, Marrari M, Fengold B, Zeeti A. Significance of anti-HLA antibodies on adult and pediatric heart allograft outcomes. Front Immunol 2017; 8:4.

32. Nunoda S. Cardiac allograft vasculopathy? Heart transplantation provides insights into pathogenesis and treatment of arteriosclerosis. Circ J 2018; 82:2943–2945.

33. Hammond EH, Yowell RL, Nunoda S, et al. Vascular (humoral) reaction in heart transplantation: pathologic observations and clinical implications. J Heart Lung Transplant 1989; 8:430–443.

34. Ho EK, Vlad G, Vaelescu ER, et al. Pre and posttransplantation allo-sensitization in heart allograft recipients: major impact of de novo alloantibody production on all-cause mortality. Hum Immunol 2011; 72:87–91.

35. Starling RC, Stehlik J, Baran DA, et al. Multicenter analysis of immune biomarkers and heart transplant outcomes: results of the clinical trials in organ transplantation (CTOT)-6 study. Am J Transplant 2016; 16:121–136.

36. Living CA, Carter V, Gennery AR, et al. Effect of persistent versus transient donor-specific HLA antibodies on graft outcomes in pediatric cardiac transplantation. J Heart Lung Transplant 2015; 34:1310–1317.

37. Tran A, Fister D, Huang R, et al. Donor-specific HLA alloantibodies: impact on cardiac allograft vasculopathy, rejection, and survival after pediatric heart transplantation. J Heart Lung Transplant 2016; 35:87–91.

38. Cole RT, Gandhi J, Bray RA, et al. De novo DQ donor-specific antibodies are associated with worse outcomes compared to non-DQ de novo donor-specific antibodies following heart transplantation. Clin Transplant 2017; 31:1–7.

The study compares outcomes in patients developing de novo donor-specific antibodies (dnDSAs) to DQ antigens with those developing non-DQ dnDSAs and those free from dnDSAs, and the patients with dnDSAs to DQ antigens following HTRs are associated with increased risk of death and graft dysfunction.

39. Kobashigawa J, Mehra M, West L, et al. Report from a consensus conference on the sensitized patient awaiting heart transplantation. J Heart Lung Transplant 2009; 28:213–225.

40. Kobashigawa JA, Patel JK, Kittle son MM, et al. The long-term outcome of treated sensitized patients who undergo heart transplantation. Clin Transplant 2011; 25:E61–E67.

41. Colvin MM, Cook JL, Chang P, et al. Antibody-mediated rejection in cardiac transplantation: emerging knowledge in diagnosis and management: a scientific statement from the American Heart Association. Circulation 2015; 131:1608–1639.

42. Schlaf G, Pollok-Kopp B, Manske T, et al. Novel solid phase-based ELISA assays contribute to an improved detection of anti-HLA antibodies and to an increased reliability of pre and posttransplant crossmatching. NDT Plus 2010; 3:527–538.

43. Won DI, Jung HD, Jung OJ, et al. Flow cytometry PRA using lymphocyte pools from random donors. Clin Cytom 2007; 72:256–264.

44. Smith JD, Hamour IM, Banner NR, Rose ML. C4d fixing, luminox binding antibodies: a new tool for prediction of graft failure after heart transplantation. Am Soc Transplant Surg 2007; 7:289–2815.

45. Chin G, Chen G, Sueria F, Berry G, et al. Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. J Heart Lung Transplant 2011; 30:159–163.

46. Chin G, Sequeira F, Yen DB. Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. Hum Immunol 2011; 72: 849–858.

47. Schaube SH, Höniger G, Koller MT, et al. Determinants of C1q binding in the single antigen bead assay. Transplantation 2014; 98:387–393.

48. Kauke T, Kaczmarek I, Dick A, et al. Anti-MICA antibodies are related to adverse outcome in heart transplant recipients. J Heart Lung Transplant 2009; 28:305–311.
48. Angaswamy N, Saini D, Ramachandran S, et al. Development of antibodies to human leukocyte antigen precedes development of antibodies to major histocompatibility class I-related chain A and are significantly associated with development of chronic rejection after human lung transplantation. Hum Immunol 2010; 71:560–565.

49. Cao K, Lai C-H, Flores SV, et al. AT1R antibodies together with anti-HLA donor specific antibodies (HLA-DSA) identify patients at risk for immune complication in heart transplant. J Heart Lung Transplant 2012; 31:S163.

50. Randhawa PK, Philogene MC, Jeresano M, et al. Management of heart transplant recipients with hemodynamically significant clinical rejection in the presence of antibodies against angiotensin II type 1 receptor: a retrospective study. Trends Transplant 2018; 11:1–6.

The study shows that AT1R-Ab in heart transplant recipients appears to be associated with hemodynamic significant rejection and the use of angiotensin receptor blockade can be considered in the therapy of these patients.

51. Hiemann NE, Meyer R, Wellnhofer E, et al. Non-HLA antibodies targeting vascular receptors enhance alloimmune response and microvasculopathy after heart transplantation. Transplantation 2012; 94:919–924.

52. Faulk WP, Rose M, Meroni PL, et al. Antibodies to endothelial cells identify myocardial damage and predict development of coronary artery disease in patients with transplanted hearts. Hum Immunol 1999; 60:826–832.

53. Jurcevic S, Ainsworth ME, Pomerance A, et al. Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation. Transplantation 2001; 71:886–892.

54. Goers TA, Ramachandran S, Aloush A, et al. De novo production of K-alpha 1 tubulin-specific antibodies: role in chronic lung allograft rejection. J Immunol 2008; 180:4487–4494.

55. Iwata T, Philipovskiy A, Fisher AJ, et al. Antitype V collagen humoral immunity in lung transplant primary graft dysfunction. J Immunol 2008; 181:5738–5747.

56. Kalache S, Dinavahi R, Pinney S, et al. Anticardiac myosin immunity and chronic allograft vasculopathy in heart transplant recipients. J Immunol 2011; 187:1023–1030.

57. Zhang Q, Cecka JM, Gjertson DW, et al. HLA and MICA: targets of antibody-mediated rejection in heart transplantation. Transplantation 2011; 91:1153–1158.

58. Kobashigawa J, Crespo-Leiro MG, Ensinger SM, et al. Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 2010; 30:252–259.

59. Nath DS, Basha H, Tiriveedhi V, et al. Characterization of immune responses to cardiac self-antigens myosin and vimentin in human cardiac allograft recipients with antibody-mediated rejection and cardiac allograft vasculopathy. J Heart Lung Transplant 2010; 29:1277–1285.

60. Fredrich R, Toyoda M, Czer LS, et al. The clinical significance of antibodies to human vascular endothelial cells after cardiac transplantation. Transplantation 1999; 67:385–391.

61. Takemoto SK, Zeevi A, Feng S, et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004; 4:1033–1041.